Martial Hamon1, Gilles Lemesle2, Olivier Tricot3, Thibaud Meurice4, Michel Deneve5, Xavier Dujardin6, Jean Michel Brufau7, Jerome Bera4, Nicolas Lamblin2, Christophe Bauters8. 1. Centre Hospitalier Universitaire de Caen, Caen, France; Faculté de Médecine de Caen, Caen, France. 2. Centre Hospitalier Régional et Universitaire de Lille, Lille, France; Inserm U744, Institut Pasteur de Lille, Université Lille Nord de France, Lille, France; Faculté de Médecine de Lille, Lille, France. 3. Centre Hospitalier de Dunkerque, Dunkerque, France. 4. Polyclinique du Bois, Lille, France. 5. Centre Hospitalier Régional et Universitaire de Lille, Lille, France. 6. Centre Hospitalier de Boulogne-Sur-Mer, Boulogne-Sur-Mer, France. 7. Polyclinique Vauban, Valenciennes, France. 8. Centre Hospitalier Régional et Universitaire de Lille, Lille, France; Inserm U744, Institut Pasteur de Lille, Université Lille Nord de France, Lille, France; Faculté de Médecine de Lille, Lille, France. Electronic address: christophe.bauters@chru-lille.fr.
Abstract
BACKGROUND: Although there is evidence that patients who experience major bleeding after an acute coronary event are at higher risk of death in the months after the event, the incidence and impact on outcome of bleeding beyond 1 year of follow-up in patients with stable coronary artery disease (CAD) are largely unknown. OBJECTIVES: The goal of this study was to assess the incidence, source, determinants, and prognostic impact of major bleeding in stable CAD. METHODS: We prospectively included 4,184 consecutive CAD outpatients who were free from any myocardial infarction (MI) or coronary revascularization for >1 year at inclusion. Follow-up was performed at 2 years, with major bleeding defined as a type ≥3 bleed using the Bleeding Academic Research Consortium (BARC) definition. RESULTS: There were 51 major bleeding events during follow-up (0.6%/year). Most events were BARC type 3a bleeds with 12 fatal bleeds (type 5). In most cases (54.9%), the site of bleeding was gastrointestinal. Major bleeding was significantly associated with mortality (adjusted hazard ratio: 2.89; 95% confidence intervals: 1.73 to 4.83; p < 0.0001). The increased risk of bleeding associated with vitamin K antagonist (VKA) treatment was particularly evident when VKA was combined with an antiplatelet therapy (APT). In contrast, the risk of cardiovascular death, MI, or nonhemorrhagic stroke did not differ in patients who received VKA + APT versus patients on VKA alone. CONCLUSIONS: In patients with stable CAD (i.e., >1 year, with no acute events), major bleeding events are rare, but such events are an independent predictor of death. When oral anticoagulation is required, concomitant APT should not be prescribed in the absence of a recent cardiovascular event.
BACKGROUND: Although there is evidence that patients who experience major bleeding after an acute coronary event are at higher risk of death in the months after the event, the incidence and impact on outcome of bleeding beyond 1 year of follow-up in patients with stable coronary artery disease (CAD) are largely unknown. OBJECTIVES: The goal of this study was to assess the incidence, source, determinants, and prognostic impact of major bleeding in stable CAD. METHODS: We prospectively included 4,184 consecutive CAD outpatients who were free from any myocardial infarction (MI) or coronary revascularization for >1 year at inclusion. Follow-up was performed at 2 years, with major bleeding defined as a type ≥3 bleed using the Bleeding Academic Research Consortium (BARC) definition. RESULTS: There were 51 major bleeding events during follow-up (0.6%/year). Most events were BARC type 3a bleeds with 12 fatal bleeds (type 5). In most cases (54.9%), the site of bleeding was gastrointestinal. Major bleeding was significantly associated with mortality (adjusted hazard ratio: 2.89; 95% confidence intervals: 1.73 to 4.83; p < 0.0001). The increased risk of bleeding associated with vitamin K antagonist (VKA) treatment was particularly evident when VKA was combined with an antiplatelet therapy (APT). In contrast, the risk of cardiovascular death, MI, or nonhemorrhagic stroke did not differ in patients who received VKA + APT versus patients on VKA alone. CONCLUSIONS: In patients with stable CAD (i.e., >1 year, with no acute events), major bleeding events are rare, but such events are an independent predictor of death. When oral anticoagulation is required, concomitant APT should not be prescribed in the absence of a recent cardiovascular event.
Authors: Gilles Lemesle; Gregory Ducrocq; Yedid Elbez; Eric Van Belle; Shinya Goto; Christopher P Cannon; Christophe Bauters; Deepak L Bhatt; Philippe Gabriel Steg Journal: Clin Cardiol Date: 2017-07-10 Impact factor: 2.882
Authors: J W Zhang; W W Liu; Timothy A McCaffrey; X Q He; W Y Liang; X H Chen; X R Feng; Sidney W Fu; M L Liu Journal: Clin Interv Aging Date: 2017-08-10 Impact factor: 4.458
Authors: Francesco Costa; Jan G Tijssen; Sara Ariotti; Sara Giatti; Elisabetta Moscarella; Paolo Guastaroba; Rossana De Palma; Giuseppe Andò; Giuseppe Oreto; Felix Zijlstra; Marco Valgimigli Journal: J Am Heart Assoc Date: 2015-12-07 Impact factor: 5.501